BIOLASE Inc. (BIOL) - חוב להון עצמי

This chart illustrates the market price reflecting the total debt-to-equity ratio of BIOLASE, Inc. (BIOL), which stands at 0.00. Stability in these metrics is supported by strict FDA oversight and exclusive patents for laser systems. Its status as a global leader enables the company to maintain significant pricing power due to the painless nature of its procedures. Production also relies on compliance with RoHS standards for the disposal of electronic components.

This ratio determines financial stability by comparing total credit obligations against equity to assess the business's degree of dependence on borrowed funds. By analyzing the company's leverage relative to equity, an investor can see the balance between the debt load and the resources that BIOLASE, Inc. (BIOL) allocates toward the development of laser systems through strategic partnerships with global dental associations.